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Nebivolol is a β-blocker that is highly selective for β1-adrenergic receptors with vasodilating 
properties. This property can be attributed to an endothelial release of nitric oxide (NO). It has 
been reported that nebivolol also reduces intracellular oxidative stress. There are some 
studies conducted in humans and animal models which have shown that NO is an important 
regulator of bone metabolism. However, oxidative stress and antioxidant systems may play 
important roles in the pathogenesis of osteoporosis. In this paper, we hypothesized that 
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Introduction 
 
There is a balance in the activities of various 
types of bone cells that is carefully 
coordinated by several hormones and 
cytokines termed ‘bone remodeling’. 
Osteoporosis is characterized by low bone 
mass and microarchitectural deterioration of 
bone tissue leading to increased bone fragility 





Postmenopausal osteoporosis has been 
described by Fuller Albright
2
 as the 
consequence of impaired bone formation due 
to oestrogen deficiency. Oestrogen induces 
endothelial nitric oxide (NO) production
3
, and 
the protective effect of estrogen in bone may 
be mediated in this way. NO stimulates 
osteoblast proliferation
4
. There are several 
drugs that are used for osteoporosis 
treatment. We think that nebivolol may be a 
choice in osteoporosis treatment by acting via 
NO. 
 
Mechanism of Action of Nebivolol 
and Nitric Oxide 
 
Beta-blockers are one of the drugs of choice 
for the treatment of hypertension
1
, and have 
been commercially available for nearly fifty 
years. Recently, several beta-blockers with 
different mechanisms of action and 
antihypertensive efficacy have come into use. 
Beta-blocker mechanisms are very interesting. 
Reta-blockers are used for hypertension 
treatment and the basis is the inhibition of 
renin by beta-blockers, especially at high 
doses, in the juxtaglomerular apparatus. They 
also have some central effects because of 





In hypertensive efficacy, beta1-selective 
agents may be more effective than non-
selective beta-blockers. These include some 
among the third generation betablockers such 
as labetolol, carvedilol, bucindolol, and 
nebivolol. Currently, nebivolol is the newest of 
the beta-blockers with long acting properties; 
it is also a highly cardioselective beta1-blocker 
and is different from earlier drugs in the same 
family. Nebivolol consists of a 1:1 racemic 
mixture of d- and l-enantiomers, of which D-
nebivolol is a highly selective beta1-receptor 
antagonist. D-nebivolol shows an over 100-
fold greater affinity for β1-adrenoreceptors 
than l-enantiomer
4
. The vasorelaxant action of 
nebivolol is mediated by not only its main 
pharmacodynamic property as an adrenergic 
receptor antagonist, but also through the 
stimulation of nitric oxide (NO) release from 
vascular endothelium
5,6
. In particular, the l-
form possesses an endothelium-dependent 
vasorelaxant effect
7
. However,some studies 
indicate that nebivolol is able to induce a 
remarkable production of NO in vessels via 
the dextro-rotatory isomer. NO production is 
realized through the activation of the 





In addition nebivolol has been shown to cause 
endothelium-dependent vasodilation associa-
ted with activation of the L-arginine/nitric oxide 
(NO) pathway in both hypertensive and 
normotensive subjects
9,10
. Although the 
molecular mechanisms that could explain this 
proposed action of nebivolol on NO release 
have not been clarified, NO release can be 
induced by two different intracellular 
mechanisms. These mechanisms consist of 
the enzyme endothelial nitric oxide synthase 
(eNOS) either by its interaction with the Ca2–
calmodulin complex
11





The endothelial effect of nebivolol may result 
from the activation of different receptors such 
as β-2 and β-3 adrenoreceptors
9,13-15
, 






commonly found for other β blockers, and 
P2Y purinoceptor
6
. In various studies, it has 
been shown that nebivolol causes vasodilation 
through endothelial β2 adrenergic receptor–
mediated NO production and/or ATP efflux 




nebivolol inhibits NO synthase uncoupling
18
. 
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However, its vasodilating effect depends on 




Besides the vasodilating effect of nebivolol, it 
has antioxidant activity and its mechanism is 
due to direct reduction of reactive oxygen 
species (ROS) that is produced by 
Nicotinamide adenine dinucleotide phosphate 
NADPH oxidase system
21
. Moreover, it was 
reported that nebivolol decreases systemic 




Nebivolol is a lipophilic agent and is 
metabolized in the liver. It is transformed into 
several active metabolites, essentially via the 
cytochrome P450 2D6  (CYP2D), an isoform 
of cytochrome P450 characterized by genetic 
polymorphism
23
. It was suggested that only 
some hepatic metabolites, not the parent 




Epidemiological studies have indicated a 
higher prevalence of cardiovascular risk 
factors among African-Americans. In order to 
understand the basis for this difference, low 
bioavailability of NO from the endothelium of 
African-Americans was reported despite much 
higher levels of endothelium-dependent NO 
synthase (eNOS)
24
. The observed higher 
prevalence of cardiovascular risk factors and 
their complications among African-Americans 
may be explained by this polymorphism. 
 
Nebivolol is able to induce a significant 
increase in NO which is the main endogenous 
mediator of vasorelaxation in conductance 











 and murine corpus 
cavernosum
27
. Some studies had shown that 
nebivolol causes NO-dependent vaso-
dilation
5,6,9,11,12
. Moreover, Maffei et al have 
directly observed nebivolol-induced NO 
production through a NO-specific visualization 
technique
8
. It was demonstrated that nebivolol 
exerts an agonist activity on β3 
adrenoreceptors to induce sustained NO 
production through increases in cytosolic 
calcium concentrations and dephosphorylation 
of threonine 495 endothelial NO synthase 
(Thr495-eNOS)
14
. The novel β-blocker 
nebivolol has been shown to increase 
synthesis and release of endothelium-
dependent NO which plays an important role 
in the regulation of vascular structure, tone, 
and function, and endothelial dysfunction 
which plays an important role in the 
pathogenesis of hypertension and cardio 
vascular disease (CVD). 
 
Nitric oxide and Osteoporosis 
 
Nitric oxide (NO), a type of short-lived 
signaling molecule, plays important roles in 
several biological processes including bone 
cell functions. The production of NO from L-
arginine is catalyzed by nitric oxide synthase 
(NOS) that has three isoforms: neuronal 





Postmenopausal osteoporosis has been 
described as the consequence of impaired 
bone formation due to oestrogen deficiency. 
oestrogen seems to be important in the 
stimulation of osteoblast proliferation and 
differentiation via the NO and NOS 
pathway
29,30,31
. Although, some studies 
reported that NO is an important regulator of 
bone metabolism
32-35
, the results of these 
studies are controversial. The studies 
conducted on the effect of NO on bone cell 
functions showed that bone cells produce NO 
in response to various stimuli including 
oestrogens, pro-inflammatory cytokines, and 
mechanical stress
33-37
 and in this regard, 
different types of NOS play a role. endothelial 
NO synthase (ENOS) is the major nitric oxide 
synthase enzyme expressed in bone by 
osteoblasts, osteoclasts, and osteocytes, and 
expressed with estrogen-related receptor 
alpha (ERRα) in all these bone cells
36
. 
However, it was suggested that ERRα up-
regulates endothelial nitric oxide synthase 
(eNOS) mRNA and protein expression in 
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NO release in osteoblastic cells increases 
cyclic guanosine monophosphate  (cGMP) 
formation and cGMP signal regulates 
osteoblastic proliferation and differentiation
39
. 
Pan et al. showed that phytooestrogen, 
genistein, stimulates osteoblastic 
differentiation via NO/cGMP in primary mouse 
bone marrow-derived mesenchymal stem cell 
cultures
40
. Resveratrol is a naturally occurring 
polyphenol that possess estrogenic activity, 
suggesting that it may possess similar 
functions as oestrodiol (E2) on NO synthesis 
and osteoblastic metabolism
29
. Some studies 
suggested that treatment for 24 hours with E2 




In vitro, NO is produced by osteoblasts and 
stimulates their proliferation
41
. NO has 
biphasic effects on bone resorption. Although, 
low levels of NO production may be essential 
for normal osteoclast function and maturation, 
cytokine-induced NO has been found to inhibit 
proliferation of osteoblasts
43
. It was reported 
that nitroglycerin ointment was as effective as 




and taking nitrates increased hip bone mineral 
density (BMD) in women
45
. Moreover, 
ovariectomy-induced osteopaenia can be 
reversed by NO donor nitroglycerin in rats
46,47
. 
Corticosteroid-induced bone loss was also 





NO inhibits the osteoclasts, thus greatly 
increasing bone deposition. Vitamin K and 
magnesium (Mg) also have similar effects
49
. It 
is fact that oral administration of L-arginine in 
pharmacological doses stimulates growth 
hormone and insulin-like growth factor-I 
responses, and increases nitric oxide 
synthesis. Since nitric oxide is a potent 
inhibitor of osteoclastic bone resorption, L-
arginine could increase bone mass. 
Therefore, it is hypothesized that oral 
supplementation of L-arginine may be a new 








Previous studies have reported that oxidative 
stress and antioxidant systems play important 
roles in the development of osteoporosis
51,52
. 
We also know about the role of NO in the 
pathogenesis of osteoporosis. Nebivolol is 
able to induce a significant increase in NO 
which is the main endogenous mediator of 
vasorelaxation in various tissues. 
Furthermore, NO may have beneficial effects 
on osteoporosis. In the light of the available 
information, we hypothesized that nebivolol 
may be benefical via nitric oxide in 
osteoporosis treatment. However clinical 
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